Cosmo Pharmaceuticals announced successful voting results from its 2025 Annual General Meeting, with shareholders approving all items on the agenda. The meeting saw representation of 9,135,061 ordinary shares, constituting 52.07% of total outstanding shares. A key highlight was the approval of a €2.05 per share dividend, marking a 2.5% increase from the previous year. The dividend will be distributed with an ex-dividend date of June 4, 2025, and payment date of June 6, 2025. Chairman Alessandro Della Chà expressed gratitude for shareholders' trust, while CEO Giovanni Di Napoli announced an upcoming Investor Day scheduled for July 1 in Zurich to discuss ongoing and future projects.
Cosmo Pharmaceuticals ha comunicato i risultati positivi della votazione durante l'Assemblea Generale Annuale 2025, con gli azionisti che hanno approvato tutti i punti all'ordine del giorno. All'incontro erano rappresentate 9.135.061 azioni ordinarie, pari al 52,07% del totale delle azioni in circolazione. Un punto saliente è stato l'approvazione di un dividendo di €2,05 per azione, con un aumento del 2,5% rispetto all'anno precedente. Il dividendo sarà distribuito con data ex-dividendo il 4 giugno 2025 e pagamento il 6 giugno 2025. Il presidente Alessandro Della Chà ha espresso gratitudine per la fiducia degli azionisti, mentre l'Amministratore Delegato Giovanni Di Napoli ha annunciato una prossima Investor Day previsto per il 1° luglio a Zurigo, durante il quale saranno discussi i progetti in corso e futuri.
Cosmo Pharmaceuticals anunció resultados exitosos en la votación de su Junta General Anual 2025, con los accionistas aprobando todos los puntos del orden del día. En la reunión se representaron 9.135.061 acciones ordinarias, lo que constituye el 52,07% del total de acciones en circulación. Un aspecto destacado fue la aprobación de un dividendo de €2,05 por acción, lo que representa un aumento del 2,5% respecto al año anterior. El dividendo se distribuirá con fecha ex-dividendo el 4 de junio de 2025 y pago el 6 de junio de 2025. El presidente Alessandro Della Chà expresó su agradecimiento por la confianza de los accionistas, mientras que el CEO Giovanni Di Napoli anunció un próximo Día del Inversor programado para el 1 de julio en Zúrich para discutir proyectos actuales y futuros.
코스모 파마슈티컬스는 2025년 정기 주주총회에서 모든 안건이 주주들에 의해 승인되었다는 성공적인 투표 결과를 발표했습니다. 총 9,135,061주의 보통주가 대표되어 전체 발행 주식의 52.07%를 차지했습니다. 주요 내용으로는 주당 2.05유로의 배당금 승인으로, 전년도 대비 2.5% 증가한 수치입니다. 배당금은 2025년 6월 4일 배당락일에 분배되며, 지급일은 2025년 6월 6일입니다. 알레산드로 델라 차 회장은 주주들의 신뢰에 감사를 표했고, CEO 조반니 디 나폴리는 7월 1일 취리히에서 예정된 투자자 설명회에서 현재 및 미래 프로젝트에 대해 논의할 것이라고 밝혔습니다.
Cosmo Pharmaceuticals a annoncé les résultats positifs du vote lors de son Assemblée Générale Annuelle 2025, les actionnaires ayant approuvé tous les points à l'ordre du jour. La réunion a vu la représentation de 9 135 061 actions ordinaires, soit 52,07 % du total des actions en circulation. Un point clé a été l'approbation d'un dividende de 2,05 € par action, marquant une augmentation de 2,5 % par rapport à l'année précédente. Le dividende sera distribué avec une date ex-dividende fixée au 4 juin 2025 et une date de paiement au 6 juin 2025. Le président Alessandro Della Chà a exprimé sa gratitude envers la confiance des actionnaires, tandis que le PDG Giovanni Di Napoli a annoncé une prochaine Journée Investisseurs prévue le 1er juillet à Zurich pour discuter des projets en cours et futurs.
Cosmo Pharmaceuticals gab erfolgreiche Abstimmungsergebnisse seiner Hauptversammlung 2025 bekannt, bei der die Aktionäre alle Tagesordnungspunkte genehmigten. Auf der Versammlung waren 9.135.061 Stammaktien vertreten, was 52,07 % der ausstehenden Aktien entspricht. Ein Höhepunkt war die Genehmigung einer Dividende von 2,05 € pro Aktie, was einer Steigerung von 2,5 % gegenüber dem Vorjahr entspricht. Die Dividende wird mit einem Ex-Dividenden-Datum am 4. Juni 2025 und einem Auszahlungstermin am 6. Juni 2025 ausgeschüttet. Vorsitzender Alessandro Della Chà dankte den Aktionären für ihr Vertrauen, während CEO Giovanni Di Napoli einen Investorentag ankündigte, der am 1. Juli in Zürich stattfinden wird, um laufende und zukünftige Projekte zu besprechen.
Positive
Approved dividend of €2.05 per share, representing a 2.5% increase from previous year
Strong shareholder participation with 52.07% of total outstanding shares represented at AGM
All voting items received shareholder approval, indicating strong alignment with management
Negative
None.
Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 52.07% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Among others, the shareholders of Cosmo approved a dividend of €2.05 per share, a dividend distribution increase of 2.5% compared to the prior year. The ex-dividend date will be 4 June 2025, and payment will be made on 6 June 2025. The full voting results of the 2025 AGM and detailed dividend payment information for shareholders are available in the AGM section of the Company’s website.
Alessandro Della Chà, Chairman of Cosmo, commented:“On behalf of the entire Board, I would like to thank all our shareholders for their continued trust and their participation in this year’s Annual General Meeting. We remain committed to delivering long-term value, and we are grateful to have them on this journey with us.”
Giovanni Di Napoli, CEO of Cosmo, added:“We are now looking forward to providing our stakeholders, including financial analysts and media representatives, with further insights into our ongoing and future projects at our upcoming Investor Day on 1 July in Zurich.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
